Do any type 2 diabetes drugs reduce the risk of cardiovascular disease?

Type 2 diabetes drugs that have been shown to reduce the risk of cardiovascular disease in people with diabetes at high risk include empagliflozin and liraglutide. The results of a trial of the type 2 diabetes drugs empagliflozin and liraglutide unexpectedly demonstrated beneficial cardiovascular effects in people with type 2 diabetes who had high pre-existing cardiovascular risk.

The importance of these findings is that specific glucose-lowering therapies have been found to reduce cardiovascular disease in high-risk patients with type 2 diabetes. 

Continue Learning about Type 2 Diabetes Treatment

Important: This content reflects information from various individuals and organizations and may offer alternative or opposing points of view. It should not be used for medical advice, diagnosis or treatment. As always, you should consult with your healthcare provider about your specific health needs.